Daptomycin for the treatment of osteomyelitis and prosthetic joint infection: Retrospective analysis of efficacy and safety in an outpatient infusion center

Internet Journal of Infectious Diseases

Volumn 9, Issue 2, 2011, Pages

  Licitra, Carmelo M ^a   Crespo, Antonio ^a   Licitra, Doreen ^a   Wallis Crespo, Maria C ^a  

^a Florida Infectious Diseases Group   (United States)

Author keywords

Daptomycin; Osteomyelitis; Outpatient parenteral antimicrobial therapy; Prosthesis related infections

Indexed keywords

CEFADROXIL; CEFTRIAXONE; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; RIFAMPICIN; TETRACYCLINE; VANCOMYCIN;

ADULT; AGED; ARTICLE; BACTEREMIA; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HUMAN; INFECTIOUS ARTHRITIS; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MYALGIA; OSTEOMYELITIS; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PROSTHESIS INFECTION; PROSTHETIC JOINT INFECTION; RECURRENT INFECTION; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; TREATMENT FAILURE; UNITED STATES;

EID: 80054773221     PISSN: None     EISSN: 15288366     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Lew DP, Waldvogel FA: Osteomyelitis. Lancet; 2004; 364: 369-379.
2. Sia IG, Berbari EF, Karchmer AW: Prosthetic joint infections. Infect Dis Clin North Am; 2005; 19: 885-914.
3. Del Pozo JL, Patel R: Infection associated with prosthetic joints. N Engl J Med; 2009; 361: 787-794.
4. Steinkraus G, White R, Friedrich L: Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother; 2007; 60: 788-794.
5. Kollef MH: Limitations of vancomycin in the management of resistant staphylococcal infections. Clin Infect Dis. 2007; 45(Suppl 3): S191-S195.
6. Rybak MJ, Lomaestro BM, Rotscahfer JC, et al: Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis; 2009; 49: 325-327.
7. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A: High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med; 2006; 166: 2138-2144.
8. Soriano A, Marco F, Martinez JA, et al: Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis; 2008; 46: 193-200.
9. Lodise TP, Graves J, Evans A, et al: Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother; 2008; 52: 3315-3320.
10. Lodise TP, Lomaestro B, Graves J, Drusano GL: Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother; 2008; 52:1330-1336.
11. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL: Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis; 2009; 49: 507-514.
12. Forouzesh A, Moise PA, Sakoulas G: Vancomycin ototoxicity: a reevaluation in an era of increasing doses. Antimicrob Agents Chemother; 2009; 53: 483-486.
13. Steenbergen JN, Alder J, Thorne GM, Tally FP: Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother; 2005; 55: 283-288.
14. Cubicin® (daptomycin for injection) [prescribing information]. Lexington, MA: Cubist Pharmaceuticals, Inc., 2008.
15. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI: The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis; 2004; 38: 1673-1681.
16. Fowler VG Jr, Boucher HW, Corey GR, et al: Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med; 2006; 355: 653-665.
17. Mader JT, Adams K: Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits. Antimicrob Agents Chemother; 1989; 33: 689-692.
18. Luu QN, Buxton TB, Nelson DR, Rissing JP: Treatment of chronic experimental Staphylococcus aureus osteomyelitis with LY146032 and vancomycin. Eur J Clin Microbiol Infect Dis; 1989; 8: 562-563.
19. Rouse MS, Piper KE, Jacobson M, Jacofsky DJ, Steckelberg JM, Patel R: Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis. J Antimicrob Chemother; 2006; 57: 301-305.
20. Lamp KC, Friedrich LV, Mendez-Vigo L, Russo R: Clinical experience with daptomycin for the treatment of patients with osteomyelitis. Am J Med; 2007; 120(10 Suppl 1): S13-S20.
21. Martone WJ, Lindfield KC, Katz DE: Outpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry. Int J Clin Pract; 2008; 62: 1183-1187.
22. Crompton JA, North DS, McConnell SA, Lamp KC: Safety and efficacy of daptomycin in the treatment of osteomyelitis: results from the CORE Registry. J Chemother; 2009; 21: 414-420.
23. Antony SJ, Angelos E, Stratton CW: Clinical experience with daptomycin in patients with orthopedic-related infections. Infect Dis Clin Pract; 2006; 14: 144-149.
24. Falagas ME, Giannopoulou KP, Ntziora F, Papagelopoulos PJ: Daptomycin for treatment of patients with bone and joint infections: a systematic review of the clinical evidence. Int J Antimicrob Agents; 2007; 30: 202-209.
25. Shipton LK, Pillai S, Gold H, et al: Experience with daptomycin in Staphylococcus bone and joint infections: case series and emergence of nonsusceptibility. Infect Dis Clin Pract; 2007; 15: 324-329.
26. Seaton RA, MacConnachie AA: Experience with daptomycin in an infectious diseases service over 1 year: utility in an outpatient parenteral antibiotic programme. Int J Antimicrob Agents; 2008; 31: 492-497.
27. Balter L, Donovan BJ, Lamp KC, North DS, Friedrich LV: Evaluation of long-term outcomes in patients with osteomyelitis treated with a daptomycin-containing regimen. Internet Journal of Infectious Diseases; 2009; 7(2).
28. De Rosa FG, Mollaretti O, Cometto C, Pagani N, Montrucchio C, Di Perri G: Early experience with high-dosage daptomycin for prosthetic infections. Clin Infect Dis; 2009; 49: 1772-1773.
29. Lalani T, Boucher HW, Cosgrove SE, et al: Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia. J Antimicrob Chemother; 2008; 61: 177-182.
30. Rice DA, Mendez-Vigo L. Daptomycin in bone and joint infections: a review of the literature. Arch Orthop Trauma Surg. 2009; 129: 1495-1504.
31. Tice AD, Rehm SJ, Dalovisio JR, et al: Practice guidelines for outpatient parenteral antimicrobial therapy. Clin Infect Dis; 2004; 38: 1651-1672.
32. Weiss EC, Spencer HJ, Daily SJ, Weiss BD, Smeltzer MS: Impact of sarA on antibiotic susceptibility of Staphylococcus aureus in a catheter-associated in vitro model of biofilm formation. Antimicrob Agents Chemother; 2009; 53: 2475-2482.
33. Smith K, Perez A, Ramage G, Gemmell CG, Lang S: Comparison of biofilm-associated cell survival following in vitro exposure of methicillin-resistant Staphylococcus aureus biofilms to the antibiotics clindamycin, daptomycin, linezolid, tigecycline and vancomycin. Int J Antimicrob Agents; 2009; 33: 374-378.
34. National Institutes of Health: Study of daptomycin in subjects undergoing surgery for osteomyelitis associated with an infected prosthetic caused by staphylococci. http://www.clinicaltrials.gov/. Accessed August 23, 2010